Literature DB >> 9249205

Comparison of the in-vitro and in-vivo efficacy of FK037, vancomycin, imipenem and nafcillin against staphylococcal species.

M W Climo1, S M Markowitz, D S Williams, C G Hale-Cooper, G L Archer.   

Abstract

The activity of methicillin, oxacillin, vancomycin, imipenem and FK037 against 106 isolates of staphylococci was assessed using a microbroth dilution method with low (10(5) cfu/mL) and high (10(7) cfu/mL) inoculum sizes. Overall, FK037, an oxime-type cephem antibiotic, was as active as imipenem, but less active than vancomycin (MIC90s 25, 25 and 6.25 mg/L, respectively) at the lower inoculum. Efficiency of plating experiments were also performed to characterize phenotypic expression of resistance to FK037, imipenem and methicillin. Five of 24 isolates and 18 of 24 isolates contained subpopulations resistant to FK037 and imipenem, respectively. In a rabbit model of endocarditis, FK037 was equally effective as other antibiotics tested in the treatment of methicillin-sensitive Staphylococcus aureus infection. In the treatment of endocarditis due to a homotypic methicillin-resistant S. aureus, FK037 and vancomycin were the most active antibiotics. The presence of subpopulations resistant to imipenem and FK037, as demonstrated by efficiency of plating and high inoculum MIC testing, did not correlate with antibiotic effectiveness in the rabbit model of endocarditis. Cultures of vegetation material following treatment with imipenem and FK037 demonstrated a lower frequency of organisms resistant to FK037 when compared with imipenem. Thus FK037 shows in-vitro and in-vivo activity against some methicillin-resistant staphylococcal species.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9249205     DOI: 10.1093/jac/40.1.59

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  Successful therapy of experimental endocarditis caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and beta-lactam antibiotics.

Authors:  Paige M Fox; Russell J Lampen; Katrina S Stumpf; Gordon L Archer; Michael W Climo
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus.

Authors:  M W Climo; K Ehlert; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

3.  Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin.

Authors:  M W Climo; R L Patron; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

4.  Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin.

Authors:  R L Patron; M W Climo; B P Goldstein; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

5.  Combinations of lysostaphin with beta-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis.

Authors:  Nandini Kiri; Gordon Archer; Michael W Climo
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

6.  Role of penicillin-binding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus.

Authors:  J E Finan; G L Archer; M J Pucci; M W Climo
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

7.  Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.

Authors:  M W Climo; R L Patron; B P Goldstein; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

8.  Stability of ceftiofur sodium and cefquinome sulphate in intravenous solutions.

Authors:  Agnieszka Dołhań; Anna Jelińska; Marcelina Bębenek
Journal:  ScientificWorldJournal       Date:  2014-06-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.